NCT03789097: Vaccination With Flt3L, Radiation, and Poly-ICLC

NCT03789097
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patient has known active central nervous system metastases, leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03789097

Comments are closed.

Up ↑